F
This research group designs and develops engineered immune cell therapies utilizing synthetic immune receptors to modulate T cell function. The work focuses on systematically studying receptor signaling to create living drugs for treating autoimmune disease, cancer, and aging. They leverage chimeric antigen receptors (CARs) to impart specific targeting capabilities to T cells, particularly regulatory T cells (Tregs).
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This research group designs and develops engineered immune cell therapies utilizing synthetic immune receptors to modulate T cell function. The work focuses on systematically studying receptor signaling to create living drugs for treating autoimmune disease, cancer, and aging. They leverage chimeric antigen receptors (CARs) to impart specific targeting capabilities to T cells, particularly regulatory T cells (Tregs).